S&P 500   5,132.59 (+0.71%)
DOW   39,067.34 (+0.18%)
QQQ   445.26 (+1.43%)
AAPL   178.68 (-1.15%)
MSFT   414.89 (+0.30%)
META   502.43 (+2.51%)
GOOGL   138.18 (-0.20%)
AMZN   178.38 (+0.92%)
TSLA   204.03 (+1.06%)
NVDA   817.60 (+3.35%)
NIO   5.83 (+1.39%)
AMD   200.73 (+4.26%)
BABA   74.84 (+1.09%)
T   16.98 (+0.30%)
F   12.44 (+0.00%)
MU   95.91 (+5.85%)
CGC   3.25 (-1.22%)
GE   159.10 (+1.41%)
DIS   112.05 (+0.42%)
AMC   4.40 (+1.85%)
PFE   26.56 (+0.00%)
PYPL   60.62 (+0.46%)
XOM   105.80 (+1.22%)
S&P 500   5,132.59 (+0.71%)
DOW   39,067.34 (+0.18%)
QQQ   445.26 (+1.43%)
AAPL   178.68 (-1.15%)
MSFT   414.89 (+0.30%)
META   502.43 (+2.51%)
GOOGL   138.18 (-0.20%)
AMZN   178.38 (+0.92%)
TSLA   204.03 (+1.06%)
NVDA   817.60 (+3.35%)
NIO   5.83 (+1.39%)
AMD   200.73 (+4.26%)
BABA   74.84 (+1.09%)
T   16.98 (+0.30%)
F   12.44 (+0.00%)
MU   95.91 (+5.85%)
CGC   3.25 (-1.22%)
GE   159.10 (+1.41%)
DIS   112.05 (+0.42%)
AMC   4.40 (+1.85%)
PFE   26.56 (+0.00%)
PYPL   60.62 (+0.46%)
XOM   105.80 (+1.22%)
S&P 500   5,132.59 (+0.71%)
DOW   39,067.34 (+0.18%)
QQQ   445.26 (+1.43%)
AAPL   178.68 (-1.15%)
MSFT   414.89 (+0.30%)
META   502.43 (+2.51%)
GOOGL   138.18 (-0.20%)
AMZN   178.38 (+0.92%)
TSLA   204.03 (+1.06%)
NVDA   817.60 (+3.35%)
NIO   5.83 (+1.39%)
AMD   200.73 (+4.26%)
BABA   74.84 (+1.09%)
T   16.98 (+0.30%)
F   12.44 (+0.00%)
MU   95.91 (+5.85%)
CGC   3.25 (-1.22%)
GE   159.10 (+1.41%)
DIS   112.05 (+0.42%)
AMC   4.40 (+1.85%)
PFE   26.56 (+0.00%)
PYPL   60.62 (+0.46%)
XOM   105.80 (+1.22%)
S&P 500   5,132.59 (+0.71%)
DOW   39,067.34 (+0.18%)
QQQ   445.26 (+1.43%)
AAPL   178.68 (-1.15%)
MSFT   414.89 (+0.30%)
META   502.43 (+2.51%)
GOOGL   138.18 (-0.20%)
AMZN   178.38 (+0.92%)
TSLA   204.03 (+1.06%)
NVDA   817.60 (+3.35%)
NIO   5.83 (+1.39%)
AMD   200.73 (+4.26%)
BABA   74.84 (+1.09%)
T   16.98 (+0.30%)
F   12.44 (+0.00%)
MU   95.91 (+5.85%)
CGC   3.25 (-1.22%)
GE   159.10 (+1.41%)
DIS   112.05 (+0.42%)
AMC   4.40 (+1.85%)
PFE   26.56 (+0.00%)
PYPL   60.62 (+0.46%)
XOM   105.80 (+1.22%)
NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

$0.86
0.00 (0.00%)
(As of 02/29/2024 ET)
Today's Range
$0.86
$0.95
50-Day Range
$0.52
$1.31
52-Week Range
$0.51
$1.95
Volume
30,450 shs
Average Volume
53,583 shs
Market Capitalization
$9.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADXS stock logo

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Stock Price History

ADXS Stock News Headlines

Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Ayala Pharmaceuticals Inc Ordinary Shares ADXS
Ayala Pharmaceuticals Inc (ADXS)
Armando Ayala
Ayala Pharmaceuticals, Inc. (ADXS)
Hubei Biocause Pharmaceutical
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/09/2021
Today
3/01/2024
Next Earnings (Estimated)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXS
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
-210,876.91%

Debt

Sales & Book Value

Annual Sales
$3.24 million
Book Value
($0.61) per share

Miscellaneous

Free Float
10,684,000
Market Cap
$9.26 million
Optionable
Not Optionable
Beta
1.51
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Ruth Ben Yakar Ph.D. (Age 54)
    Chief Exec. Officer
  • Dr. Stela Gangrenovitch Ph.D.
    Co-Founder, Chief Scientist Officer and Director
  • Mr. Mark Gengrinovitch LLB
    Co-Founder, Chief Financial Officer and Director














ADXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares.
View ADXS analyst ratings
or view top-rated stocks.

How have ADXS shares performed in 2024?

Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of 2024. Since then, ADXS stock has increased by 29.1% and is now trading at $0.8610.
View the best growth stocks for 2024 here
.

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our ADXS earnings forecast
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) released its quarterly earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The business earned $0.25 million during the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXS) was last updated on 3/1/2024 by MarketBeat.com Staff